[糖尿病学视角的评论] - Suppr

Suppr

超能文献

[Comment from the diabetology viewpoint].

作者信息

Stahl Matthias

机构信息

Diabetologie/Endokrinologie, Medizinische Klinik, Kantonsspital Olten.

出版信息

Praxis (Bern 1994). 2008 Aug 27;97(17):943-4. doi: 10.1024/1661-8157.97.17.943.

DOI:10.1024/1661-8157.97.17.943

PMID:18777777

Abstract

摘要

相似文献

[Comment from the diabetology viewpoint].

Praxis (Bern 1994). 2008 Aug 27;97(17):943-4. doi: 10.1024/1661-8157.97.17.943.

[Questions for practicing internists].

Praxis (Bern 1994). 2008 Aug 27;97(17):945-6. doi: 10.1024/1661-8157.97.17.945.

[Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study].

MMW Fortschr Med. 2008 Apr 24;150(17):42-4. doi: 10.1007/BF03365441.

[Glycemic control and cardiovascular benefit: what do we know today?].

Dtsch Med Wochenschr. 2011 May;136(19):1027; author reply 1027-8. doi: 10.1055/s-0031-1275838. Epub 2011 May 3.

Is glycemic control a quinidine-like intervention?

J Diabetes. 2014 Sep;6(5):387-8. doi: 10.1111/1753-0407.12170. Epub 2014 Jul 16.

Learning from ORIGIN.

J Diabetes. 2012 Sep;4(3):191-2. doi: 10.1111/j.1753-0407.2012.00215.x.

Decrease mortality in type II diabetes mellitus: glycemic and renal function control.

J Cardiovasc Med (Hagerstown). 2018 Feb;19 Suppl 1:e13-e15. doi: 10.2459/JCM.0000000000000586.

Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.

Cardiovasc Diabetol. 2018 Aug 22;17(1):117. doi: 10.1186/s12933-018-0760-6.

New insights into the older hypoglycemic agents in type 2 diabetes therapy.

J Diabetes. 2020 Nov;12(11):844-847. doi: 10.1111/1753-0407.13096. Epub 2020 Aug 7.

Daily glycaemic variability: benefits of optimal control.

Diabetes Obes Metab. 2013 Sep;15 Suppl 2:1-2. doi: 10.1111/dom.12139.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[Comment from the diabetology viewpoint].

Praxis (Bern 1994). 2008 Aug 27;97(17):943-4. doi: 10.1024/1661-8157.97.17.943.

[Questions for practicing internists].

Praxis (Bern 1994). 2008 Aug 27;97(17):945-6. doi: 10.1024/1661-8157.97.17.945.

[Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study].

MMW Fortschr Med. 2008 Apr 24;150(17):42-4. doi: 10.1007/BF03365441.

[Glycemic control and cardiovascular benefit: what do we know today?].

Dtsch Med Wochenschr. 2011 May;136(19):1027; author reply 1027-8. doi: 10.1055/s-0031-1275838. Epub 2011 May 3.

Is glycemic control a quinidine-like intervention?

J Diabetes. 2014 Sep;6(5):387-8. doi: 10.1111/1753-0407.12170. Epub 2014 Jul 16.

Learning from ORIGIN.

J Diabetes. 2012 Sep;4(3):191-2. doi: 10.1111/j.1753-0407.2012.00215.x.

Decrease mortality in type II diabetes mellitus: glycemic and renal function control.

J Cardiovasc Med (Hagerstown). 2018 Feb;19 Suppl 1:e13-e15. doi: 10.2459/JCM.0000000000000586.

Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.

Cardiovasc Diabetol. 2018 Aug 22;17(1):117. doi: 10.1186/s12933-018-0760-6.

New insights into the older hypoglycemic agents in type 2 diabetes therapy.

J Diabetes. 2020 Nov;12(11):844-847. doi: 10.1111/1753-0407.13096. Epub 2020 Aug 7.

Daily glycaemic variability: benefits of optimal control.

Diabetes Obes Metab. 2013 Sep;15 Suppl 2:1-2. doi: 10.1111/dom.12139.